![XiuGui Chen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
XiuGui Chen
Director Técnico/Científico/I+D en TYK Medicines, Inc. .
Cargos activos de XiuGui Chen
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
TYK Medicines, Inc.
![]() TYK Medicines, Inc. Pharmaceuticals: MajorHealth Technology TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the business of research, development and commercialization of pharmaceutical products and differentiated targeted therapies to address unmet medical needs in cancer treatment. The company was founded by Wu Yusheng on November 2, 2017 and is headquartered in Huzhou, China. | Director Técnico/Científico/I+D | 01/08/2018 | - |
Historial de carrera de XiuGui Chen
Antiguos cargos conocidos de XiuGui Chen.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
![]() Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Director Técnico/Científico/I+D | - | - |
Formación de XiuGui Chen.
Shanghai University | Doctorate Degree |
Estadísticas
Internacional
China | 4 |
Operativa
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
![]() Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Health Technology |
TYK Medicines, Inc.
![]() TYK Medicines, Inc. Pharmaceuticals: MajorHealth Technology TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the business of research, development and commercialization of pharmaceutical products and differentiated targeted therapies to address unmet medical needs in cancer treatment. The company was founded by Wu Yusheng on November 2, 2017 and is headquartered in Huzhou, China. | Health Technology |
- Bolsa de valores
- Insiders
- XiuGui Chen
- Experiencia